Literature DB >> 29219

Emergence of multiply resistant pneumococci.

M R Jacobs, H J Koornhof, R M Robins-Browne, C M Stevenson, Z A Vermaak, I Freiman, G B Miller, M A Witcomb, M Isaäcson, J I Ward, R Austrian.   

Abstract

Multiple antimicrobial resistance in pneumococci was detected in Johannesburg in July, 1977, and prompted an investigation of the prevalence of resistant strains in two hospitals. Carriers of Types 6A and 19A penicillin-resistant pneumococci, resistant to antibiotic concentrations ranging between 0.12 and 4 microgram per milliliter were found in 29 per cent of 543 pediatric patients and 2 per cent of 434 hospital staff members. Multiply resistant Type 19A strains, resistant to beta-lactam antibiotics, erythromycin, clindamycin, tetracycline and chloramphenicol, were isolated from 128 carriers, and were responsible for bacteremia in four patients. Isolates from 40 other carriers were resistant to penicillin alone or to penicillin and chloramphenicol or to penicillin, chloramphenicol and tetracycline. Pneumococci can be screened for penicillin resistance with a modified Kirby--Bauer technic; the strains with zones of less than 35 mm around 6-microgram penicillin disks or less than 25 mm around 5-microgram methicillin disks should be tested for sensitivity to penicillin by measurements of minimum inhibitory concentration.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 29219     DOI: 10.1056/NEJM197810052991402

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  140 in total

1.  Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm(B) and mef(A)) in South Africa.

Authors:  L McGee; K P Klugman; A Wasas; T Capper; A Brink
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network.

Authors:  L McGee; L McDougal; J Zhou; B G Spratt; F C Tenover; R George; R Hakenbeck; W Hryniewicz; J C Lefévre; A Tomasz; K P Klugman
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

Review 3.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

4.  Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

Review 5.  Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.

Authors:  José L Martínez; Fernando Baquero
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

6.  rpoB mutations in Streptococcus mitis clinical isolates resistant to rifampin.

Authors:  Wafa Achour; Olfa Guenni; Marguerite Fines; Roland Leclercq; Assia Ben Hassen
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 7.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

8.  Penicillin-binding components of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae.

Authors:  P B Percheson; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

9.  Susceptibility of multiply antibiotic-resistant pneumococci to the new beta-lactam drugs and rosaramicin.

Authors:  S H Landesman; M Cummings; A Gruarin; H Bernheimer
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

10.  Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin.

Authors:  M E Gombert; T M Aulicino
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.